Lipella Pharmaceuticals Inc. Research and Development Expense
Lipella Pharmaceuticals Inc. (LIPO) reported Research and Development Expense of $720.97 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-14
- Lipella Pharmaceuticals Inc. research and development expense for the quarter ending 2025-09-30 was $720.97K, a 31.12% decline year-over-year.
- Lipella Pharmaceuticals Inc. research and development expense for the quarter ending 2025-06-30 was $791.58K, a 19.65% increase year-over-year.
- Lipella Pharmaceuticals Inc. research and development expense for the quarter ending 2025-03-31 was $993.48K, a 17.91% increase year-over-year.
- Lipella Pharmaceuticals Inc. research and development expense for the quarter ending 2024-12-31 was $1.06M, a 133.89% increase year-over-year.
- Lipella Pharmaceuticals Inc. research and development expense for fiscal 2024 was $3.61M, a 18.90% increase from fiscal 2023.
- Lipella Pharmaceuticals Inc. research and development expense for fiscal 2023 was $3.04M, a 19.28% increase from fiscal 2022.
- Lipella Pharmaceuticals Inc. research and development expense for fiscal 2022 was $2.55M, a 74.88% increase from fiscal 2021.
- Lipella Pharmaceuticals Inc. research and development expense for fiscal 2021 was $1.46M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $720.97K 10-Q · filed 2025-11-14 | $1.51M derived: sum of 2 quarters · filed 2025-11-14 | $2.51M 10-Q · filed 2025-11-14 | $3.57M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | $791.58K 10-Q · filed 2025-08-14 | $1.79M 10-Q · filed 2025-08-14 | $2.85M derived: sum of 3 quarters · filed 2025-08-14 | $3.89M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-03-31 | $993.48K 10-Q · filed 2025-05-14 | $2.06M derived: sum of 2 quarters · filed 2025-05-14 | $3.10M derived: sum of 3 quarters · filed 2025-11-14 | $3.76M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.11M derived: sum of 2 quarters · filed 2025-11-14 | $2.77M derived: sum of 3 quarters · filed 2025-11-14 | $3.61M 10-K · filed 2025-03-28 |
| 2024-09-30 | $1.05M 10-Q · filed 2025-11-14 | $1.71M derived: sum of 2 quarters · filed 2025-11-14 | $2.55M 10-Q · filed 2025-11-14 | $3.01M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $661.56K 10-Q · filed 2025-08-14 | $1.50M 10-Q · filed 2025-08-14 | $1.96M derived: sum of 3 quarters · filed 2025-08-14 | $2.79M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $842.60K 10-Q · filed 2025-05-14 | $1.30M derived: sum of 2 quarters · filed 2025-05-14 | $2.13M derived: sum of 3 quarters · filed 2025-05-14 | $3.19M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $454.20K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.29M derived: sum of 2 quarters · filed 2025-03-28 | $2.35M derived: sum of 3 quarters · filed 2025-03-28 | $3.04M 10-K · filed 2025-03-28 |
| 2023-09-30 | $833.26K 10-Q · filed 2024-11-14 | $1.89M derived: sum of 2 quarters · filed 2024-11-14 | $2.58M 10-Q · filed 2024-11-14 | $3.06M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.06M 10-Q · filed 2024-08-13 | $1.75M 10-Q · filed 2024-08-13 | $2.23M derived: sum of 3 quarters · filed 2024-08-13 | $2.88M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $693.73K 10-Q · filed 2024-05-09 | $1.17M derived: sum of 2 quarters · filed 2024-05-09 | $1.82M derived: sum of 3 quarters · filed 2024-05-09 | $2.57M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $478.10K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.13M derived: sum of 2 quarters · filed 2024-02-27 | $1.87M derived: sum of 3 quarters · filed 2024-02-27 | $2.55M 10-K · filed 2024-02-27 |
| 2022-09-30 | $650.95K 10-Q · filed 2023-11-14 | $1.39M derived: sum of 2 quarters · filed 2023-11-14 | $2.07M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $742.66K 10-Q · filed 2023-08-14 | $1.42M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $675.96K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $1.46M 10-K · filed 2023-03-31 |